Use of parapox B2L protein to modify immune responses to administered antigens
AssigneeBoard of Regents, The University of Texas System
InventorsStephen A. Johnston, Michael J. McGuire
Life of this patent
Estimating the term…
Abstract
The Parapox B2L virus envelope protein is used as an adjuvant to enhance a subject's response to an administered antigen. Both antibody and cellular immune responses can be modified. B2L protein is particularly useful as an adjuvant for poorly immunogenic tumor vaccines and subunit vaccines, such as those useful for preventing and/or treating flu, tuberculosis, respiratory syncytial virus, anthrax and HIV.
Claims15
A method of enhancing an immune response to an antigen, comprising the steps of:
- administering to a subject mammal in need thereof (a) an effective amount of a B2L viral envelope protein of a Parapox virus, wherein the B2L protein is unassociated with other envelope components naturally associated with the B2L protein in the virus, and (b) an antigen, whereby the B2L protein acts as an adjuvant to enhance the immune response to the antigen;
- and
- detecting a resultant enhanced, specific immune response to the antigen.
A pharmaceutical composition for enhancing an immune response to an antigen, the composition comprising:
- a B2L viral envelope protein of a Parapox virus, or a nucleic acid encoding said B2L protein, wherein the B2L protein is unassociated with other envelope components naturally associated with the B2L protein in the virus;
- and
- an antigen or a nucleic acid encoding said antigen, wherein administered to a subject mammal in need thereof, the B2L protein of the pharmaceutical composition acts as an adjuvant to enhance a specific immune response to the antigen.
A method of enhancing an immune response to an antigen, comprising the steps of:
- administering to a subject mammal in need thereof (a) an effective amount of a PP30 protein of a Parapox virus, wherein the PP30 protein as found in Parapox strain D1701 comprises the amino acid sequence of SEQ ID NO:6, and wherein the PP30 protein is unassociated with other components naturally associated with the PP30 protein in the virus, and (b) an antigen, whereby the PP30 protein acts as an adjuvant to enhance the immune response to the antigen;
- and
- detecting a resultant enhanced, specific immune response to the antigen.
A pharmaceutical composition for enhancing an immune response to an antigen, the composition comprising:
- a PP30 protein of a Parapox virus, or a nucleic acid encoding said PP30 protein, wherein the PP30 protein is unassociated with other components naturally associated with the PP30 protein in the virus;
- and
- an antigen or a nucleic acid encoding said antigen, wherein administered to a subject mammal in need thereof, the PP30 protein of the pharmaceutical composition acts as an adjuvant to enhance a specific immune response to the antigen.
Dependencies are inferred from the claim text.